1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

How NGM Bio Intends To Build An Old-School Biotech

 
• By Mike Ward

NGM Biopharmaceuticals CEO Jeff Jonker discusses the company's lead program in NASH and its other R&D activities and business strategy in an interview with Scrip's Mike Ward.

Video interview
NGM Bio's Jeff Jonker talks NASH

With the hepatitis C challenge broadly solved, the leading cause of expensive liver transplants is now a disease called non-alcoholic steatohepatitis (NASH), which, not surprisingly, is attracting a lot of attention from companies looking to develop treatments.

Jeff Jonker, president of NGM Biopharmaceuticals Inc., a San Francisco-based biotech, explains to Scrip how he is positioning its...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

Zydus Beats Gilead, Ipsen On Cholangitis Primary Endpoint But Pruritus Data Is Key

 
• By Vibha Ravi

Zydus's saroglitazar beat both Gilead’s Livdelzi and Ipsen’s Iqirvo on biochemical response in topline results from a Phase IIb/III trial in primary biliary cholangitis, but subtle differences in definitions, data on pruritus or itching and other factors could be key to approval and adoption.

The Expanding MASH Market: How Rezdiffra, Wegovy Might Coexist

 
• By Joseph Haas

FDA approval of Novo Nordisk's Wegovy for MASH was almost as anticipated as approval of the first drug, Madrigal's Rezdiffra. Now, the MASH treatment paradigm should evolve.

Novo Adds Another Prong To Its RNA Ambitions With Replicate Deal

 
• By Jessica Merrill

Replicate is a clinical-stage company developing a next-generation self-replicating RNA technology. CEO Nathanial Wang talked to Scrip about the deal.

Obesity Beyond GLP-1s: Myostatins – Too Important To Be Ignored?

 
• By Aakash Babu

In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years. After exploring the potential of amylin receptor agonists, we now look at myostatins, which analysts expect to generate peak sales of $30bn.

More from Therapy Areas

AL-S Pharma’s AP-101 Shows Efficacy In ALS Clinical Trial

 
• By Jessica Merrill

The Phase II study tested AP-101 safety and tolerability as the primary endpoint but showed “clinically meaningful” efficacy in exploratory endpoints.

Xoma On Its Royalty Model And Cleaning Up ‘Zombie’ Companies

 
• By Manas Mishra and Andrew McConaghie

Seizing an opportunity to buy out struggling 'zombie' biotechs, Xoma is helping to return investor cash and pick up potential bargain assets for itself. Its CEO and chief investment officer explained their approach to Scrip.

Sanofi Shares Slide Despite Amlitelimab Eczema Win

 
• By Kevin Grogan

The OX40 ligand-targeting drug’s efficacy is seen as light compared with existing therapies.